Regulation of embryonic haematopoietic multipotency by EZH1

  • Nature volume 553, pages 506510 (25 January 2018)
  • doi:10.1038/nature25435
  • Download Citation
Published online:


All haematopoietic cell lineages that circulate in the blood of adult mammals derive from multipotent haematopoietic stem cells (HSCs)1. By contrast, in the blood of mammalian embryos, lineage-restricted progenitors arise first, independently of HSCs, which only emerge later in gestation2,3. As best defined in the mouse, ‘primitive’ progenitors first appear in the yolk sac at 7.5 days post-coitum2,3. Subsequently, erythroid–myeloid progenitors that express fetal haemoglobin4, as well as fetal lymphoid progenitors5, develop in the yolk sac and the embryo proper, but these cells lack HSC potential. Ultimately, ‘definitive’ HSCs with long-term, multilineage potential and the ability to engraft irradiated adults emerge at 10.5 days post-coitum from arterial endothelium in the aorta-gonad-mesonephros and other haemogenic vasculature3. The molecular mechanisms of this reverse progression of haematopoietic ontogeny remain unexplained. We hypothesized that the definitive haematopoietic program might be actively repressed in early embryogenesis through epigenetic silencing6, and that alleviating this repression would elicit multipotency in otherwise lineage-restricted haematopoietic progenitors. Here we show that reduced expression of the Polycomb group protein EZH1 enhances multi-lymphoid output from human pluripotent stem cells. In addition, Ezh1 deficiency in mouse embryos results in precocious emergence of functional definitive HSCs in vivo. Thus, we identify EZH1 as a repressor of haematopoietic multipotency in the early mammalian embryo.

  • Subscribe to Nature for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


Primary accessions

Gene Expression Omnibus


  1. 1.

    & Hematopoiesis: an evolving paradigm for stem cell biology. Cell 132, 631–644 (2008)

  2. 2.

    , & Embryonic origin of the adult hematopoietic system: advances and questions. Development 138, 1017–1031 (2011)

  3. 3.

    & Of lineage and legacy: the development of mammalian hematopoietic stem cells. Nat. Immunol. 9, 129–136 (2008)

  4. 4.

    et al. Distinct sources of hematopoietic progenitors emerge before HSCs and provide functional blood cells in the mammalian embryo. Cell Rep. 11, 1892–1904 (2015)

  5. 5.

    et al. Lymphomyeloid contribution of an immune-restricted progenitor emerging prior to definitive hematopoietic stem cells. Cell Stem Cell 13, 535–548 (2013)

  6. 6.

    & Epigenetics of haematopoietic cell development. Nat. Rev. Immunol. 11, 478–488 (2011)

  7. 7.

    et al. Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors. Cell Stem Cell 13, 459–470 (2013)

  8. 8.

    et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 32, 491–502 (2008)

  9. 9.

    et al. The transcriptional architecture of early human hematopoiesis identifies multilevel control of lymphoid commitment. Nat. Immunol. 14, 756–763 (2013)

  10. 10.

    et al. Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo. Immunity 16, 661–672 (2002)

  11. 11.

    et al. Hierarchical organization and early hematopoietic specification of the developing HSC lineage in the AGM region. J. Exp. Med. 208, 1305–1315 (2011)

  12. 12.

    et al. In vivo imaging of haematopoietic cells emerging from the mouse aortic endothelium. Nature 464, 116–120 (2010)

  13. 13.

    et al. Reprogramming committed murine blood cells to induced hematopoietic stem cells with defined factors. Cell 157, 549–564 (2014)

  14. 14.

    et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat. Genet. 41, 1006–1010 (2009)

  15. 15.

    et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128, 325–339 (2007)

  16. 16.

    et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315–326 (2006)

  17. 17.

    et al. Developmental control of Polycomb subunit composition by GATA factors mediates a switch to non-canonical functions. Mol. Cell 57, 304–316 (2015)

  18. 18.

    et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol. Cell 32, 503–518 (2008)

  19. 19.

    et al. Notch1 acts via Foxc2 to promote definitive hematopoiesis via effects on hemogenic endothelium. Blood 125, 1418–1426 (2015)

  20. 20.

    et al. Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition. Nat. Chem. Biol. 12, 672–679 (2016)

  21. 21.

    , , , & Development of hematopoietic stem cell activity in the mouse embryo. Immunity 1, 291–301 (1994)

  22. 22.

    et al. Characterization of definitive lymphohematopoietic stem cells in the day 9 murine yolk sac. Immunity 7, 335–344 (1997)

  23. 23.

    et al. Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis. Blood 126, 167–175 (2015)

  24. 24.

    et al. Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. Cell Stem Cell 14, 68–80 (2014)

  25. 25.

    et al. Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activity. PLoS Biol. 6, e93 (2008)

  26. 26.

    et al. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 107, 2170–2179 (2006)

  27. 27.

    et al. Haploinsufficiency of AML1 affects the temporal and spatial generation of hematopoietic stem cells in the mouse embryo. Immunity 13, 423–431 (2000)

  28. 28.

    et al. Haematopoietic stem and progenitor cells from human pluripotent stem cells. Nature 545, 432–438 (2017)

  29. 29.

    , , , & MAnorm: a robust model for quantitative comparison of ChIP–seq data sets. Genome Biol. 13, R16 (2012)

  30. 30.

    et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495–501 (2010)

  31. 31.

    et al. CellNet: network biology applied to stem cell engineering. Cell 158, 903–915 (2014)

  32. 32.

    , , & CEAS: cis-regulatory element annotation system. Bioinformatics 25, 2605–2606 (2009)

  33. 33.

    , & Haematopoietic progenitor and lymphoid differentiation from human pluripotent stem cells. Protoc. Exch. (2018)

  34. 34.

    et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451, 141–146 (2008)

  35. 35.

    et al. Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. Blood 102, 906–915 (2003)

  36. 36.

    et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature 483, 598–602 (2012)

  37. 37.

    & The OP9-DL1 system: generation of T-lymphocytes from embryonic or hematopoietic stem cells in vitro. Cold Spring Harb. Protoc. 2009, (2009)

  38. 38.

    et al. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat. Biotechnol. 31, 46–53 (2013)

  39. 39.

    , , , & Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10, 1213–1218 (2013)

  40. 40.

    , , & Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009)

  41. 41.

    et al. Model-based analysis of ChIP–seq (MACS). Genome Biol. 9, R137 (2008)

  42. 42.

    et al. Dynamic control of enhancer repertoires drives lineage and stage-specific transcription during hematopoiesis. Dev. Cell 36, 9–23 (2016)

  43. 43.

    , , & Use of in vivo biotinylation to study protein–protein and protein–DNA interactions in mouse embryonic stem cells. Nat. Protoc. 4, 506–517 (2009)

  44. 44.

    et al. Human definitive haemogenic endothelium and arterial vascular endothelium represent distinct lineages. Nat. Cell Biol. 17, 580–591 (2015)

  45. 45.

    et al. Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. Nat. Immunol. 11, 585–593 (2010)

Download references


We thank T. Jenuwein for sharing the Ezh1 mutant mice, which were generated at the Research Institute of Molecular Pathology (IMP, Vienna) in 2000 by D. O’Carroll (laboratory of T. Jenuwein) with the help of M. Sibilia (laboratory of E. Wagner). We also thank T. Schlaeger and the hESC Core Facility at Boston Children’s Hospital for providing pluripotent stem-cell lines, R. Mathieu from BCH Flow Cytometry Core, and M. J. Chen for technical advice. This work was supported by grants from the NIH NIDDK (R24-DK092760, R24-DK49216) and NHLBI Progenitor Cell Biology Consortium (U01-HL100001); NHLBI R01HL04880 and NIH R24OD017870-01. L.T.V. is supported by the NSF Graduate Research Fellowship. M.A.K. is supported by T32 NIH Training Grant from BWH Hematology. M.C. is supported by a fellowship from the Leukemia and Lymphoma Society. S.D. is supported by K99 NIH NHLBI award (1K99HL123484). S.H.O. is an Investigator of the Howard Hughes Medical Institute. J.X. is supported by NIH grants (K01DK093543 and R01DK111430) and a Cancer Prevention and Research Institute of Texas (CPRIT) New Investigator award (RR140025). G.Q.D. was supported by the Howard Hughes Medical Institute, and is an associate member of the Broad Institute and an investigator of the Manton Center for Orphan Disease Research.

Author information


  1. Stem Cell Program, Boston Children’s Hospital, Boston, Massachusetts, USA

    • Linda T. Vo
    • , Melissa A. Kinney
    • , Jessica Barragan
    • , Patricia M. Sousa
    • , Deepak K. Jha
    • , Areum Han
    • , Marcella Cesana
    •  & George Q. Daley
  2. Division of Hematology/Oncology, Boston Children’s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA

    • Linda T. Vo
    • , Melissa A. Kinney
    • , Jessica Barragan
    • , Patricia M. Sousa
    • , Deepak K. Jha
    • , Areum Han
    • , Marcella Cesana
    • , Stuart H. Orkin
    •  & George Q. Daley
  3. Harvard Medical School, Boston, Massachusetts, USA

    • Linda T. Vo
    • , Stuart H. Orkin
    •  & George Q. Daley
  4. Children’s Medical Center Research Institute, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA

    • Xin Liu
    • , Yuannyu Zhang
    •  & Jian Xu
  5. Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China

    • Yuannyu Zhang
    •  & Zhen Shao
  6. Department of Pathology, Beth Israel-Deaconess Medical Center, Boston, Massachusetts, USA

    • Trista E. North
  7. Howard Hughes Medical Institute, Boston, Massachusetts, USA

    • Stuart H. Orkin
  8. Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington, USA

    • Sergei Doulatov


  1. Search for Linda T. Vo in:

  2. Search for Melissa A. Kinney in:

  3. Search for Xin Liu in:

  4. Search for Yuannyu Zhang in:

  5. Search for Jessica Barragan in:

  6. Search for Patricia M. Sousa in:

  7. Search for Deepak K. Jha in:

  8. Search for Areum Han in:

  9. Search for Marcella Cesana in:

  10. Search for Zhen Shao in:

  11. Search for Trista E. North in:

  12. Search for Stuart H. Orkin in:

  13. Search for Sergei Doulatov in:

  14. Search for Jian Xu in:

  15. Search for George Q. Daley in:


L.T.V., S.D. and G.Q.D. conceived the project. L.T.V. designed all experiments, performed all pluripotent stem-cell and mouse transplantation studies and interpreted data. M.A.K. analysed RNA-seq, ChIP–seq and ATAC–seq data, performed all network analyses and interpreted data. X.L. performed ChIP–seq and ATAC–seq experiments. Y.Z. and Z.S. analysed ChIP–seq and ATAC–seq data. J.B. performed and analysed qPCR and western blot validations, assisted with tissue culture, animal dissections and mouse transplantation studies. P.M.S. assisted with timed matings, animal dissections and mouse transplantation studies. D.K.J. performed western blot validations, cloned the Ezh2-mCherry overexpression construct, assisted with ChIP–seq optimization and interpreted data. M.C. assisted with ChIP–seq optimization. A.H. assisted with RNA-seq analysis. T.E.N., S.H.O., S.D., J.X. and G.Q.D. supervised research, interpreted data and participated in project planning. L.T.V., T.E.N., S.D. and G.Q.D. wrote the manuscript with input from all co-authors.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to George Q. Daley.

Reviewer Information Nature thanks B. Gottgens, H. Mikkola and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    This file contains the uncropped gels and a list of sequences used in the manuscript.

  2. 2.

    Life Sciences Reporting Summary


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.